Drug intelligence / Profile preview

DF-007

Development stage: Preclinical
Lead developer: Drug Farm
Modality: Small Molecules

Overview

DF-007 is an investigational small molecule drug candidate being developed by Drug Farm for the treatment of cancer. The compound was identified using Drug Farm's proprietary Medusa platform, which integrates artificial intelligence with *in vivo* genetics—specifically *piggyBac* transposon-mediated mutagenesis in mice—to discover novel therapeutic targets. As of early 2024, DF-007 is in the IND-enabling stage of development. While the specific molecular target and mechanism of action remain proprietary and undisclosed, the program is a key component of the company's oncology pipeline, which focuses on first-in-class therapeutics for high-unmet-need diseases.

Beyond the preview

Go deeper on DF-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DF-007.

Explore the full profile